LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 38 filers reported holding LYRA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,882,067 | -4.9% | 12,757,562 | 0.0% | 1.66% | +9.6% |
Q2 2023 | $52,433,579 | +185.2% | 12,757,562 | +39.5% | 1.52% | +179.6% |
Q1 2023 | $18,384,927 | -36.0% | 9,146,730 | 0.0% | 0.54% | -32.6% |
Q4 2022 | $28,720,732 | -37.3% | 9,146,730 | 0.0% | 0.81% | -39.4% |
Q3 2022 | $45,825,000 | -11.3% | 9,146,730 | 0.0% | 1.33% | -17.9% |
Q2 2022 | $51,679,000 | +298.9% | 9,146,730 | +183.8% | 1.62% | +522.7% |
Q1 2022 | $12,955,000 | -53.9% | 3,222,560 | -50.0% | 0.26% | +19.8% |
Q4 2021 | $28,100,000 | -4.4% | 6,445,120 | +100.0% | 0.22% | -49.2% |
Q3 2021 | $29,403,000 | -43.2% | 3,222,560 | -50.0% | 0.43% | +27.1% |
Q2 2021 | $51,754,000 | +38.6% | 6,445,120 | +100.0% | 0.34% | -28.8% |
Q1 2021 | $37,349,000 | +1.7% | 3,222,560 | -0.0% | 0.47% | +19.8% |
Q4 2020 | $36,737,000 | +2.0% | 3,222,561 | 0.0% | 0.39% | -25.1% |
Q3 2020 | $36,028,000 | -1.4% | 3,222,561 | 0.0% | 0.53% | -11.1% |
Q2 2020 | $36,543,000 | – | 3,222,561 | – | 0.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 2,780,261 | $10,870,821 | 3.33% |
Perceptive Advisors | 12,757,562 | $49,882,067 | 1.66% |
Nantahala Capital Management | 4,050,218 | $15,836,352 | 1.35% |
PURA VIDA INVESTMENTS, LLC | 1,413,242 | $5,525,776 | 1.04% |
Ikarian Capital, LLC | 1,254,384 | $4,904,641 | 0.59% |
Parkman Healthcare Partners LLC | 625,056 | $2,443,969 | 0.45% |
VR Adviser, LLC | 924,170 | $3,613,505 | 0.38% |
Soleus Capital Management, L.P. | 592,417 | $2,316,350 | 0.21% |
ARMISTICE CAPITAL, LLC | 1,550,000 | $6,060,500 | 0.09% |
Clearline Capital LP | 119,128 | $465,790 | 0.04% |